Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea
Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...
Hosted on MSN14h
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close.
This Company Just Initiated a Quarterly Dividend: Time to Buy?
Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...
manilatimes22h
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® ...